Charlottesville, VIRGINIA5 Active Studies

Osteogenesis Imperfecta Clinical Trials in Charlottesville, VIRGINIA

Find 5 actively recruiting osteogenesis imperfecta clinical trials in Charlottesville, VIRGINIA. Connect with local research sites and explore new treatment options.

5
Active Trials
5
Sponsors
645
Enrolling

Recruiting Osteogenesis Imperfecta Studies in Charlottesville

RecruitingCharlottesville, VIRGINIANCT05732103

A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes

The goal of this phase 1/2 multicenter, open-label, single-arm dose escalation and expansion study is to assess the safety, tolerability, pharmacokinetic and pharmacodynamic profile of CTX-712 in pati...

225 participants
Chordia Therapeutics, Inc.
View Study Details
RecruitingCharlottesville, VIRGINIANCT06864169

A Study of Raludotatug Deruxtecan (R-DXd) in People With Gastrointestinal Cancers (MK-5909-005)

Researchers are looking for new ways to treat certain types of advanced gastrointestinal (GI) cancers. The study medicine raludotatug deruxtecan (also called MK-5909, R-DXd, or DS-6000a) is a type of ...

160 participants
Merck Sharp & Dohme LLC
View Study Details
RecruitingCharlottesville, VIRGINIANCT07087054

Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen

A Phase 3, randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of paltusotine treatment vs placebo as well as the long-term safety of paltusotine in adults with ca...

141 participants
Crinetics Pharmaceuticals Inc.
View Study Details
RecruitingCharlottesville, VIRGINIANCT05503355

A Phase I/II Dose Escalation and Expansion Study of BST-236 Plus Venetoclax in Patients With Unfit Newly Diagnosed AML

An open label multi centre study to assess the safety and efficacy of BST-236 in combination with venetoclax in adult patients unfit for standard therapy with newly diagnosed Acute Myeloid Leukemia (A...

80 participants
BioSight Ltd.
View Study Details
RecruitingCharlottesville, VIRGINIANCT06382168

DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia

This Phase I/II trial evaluates the safety and preliminary efficacy of DFP-10917 combined with venetoclax in relapsed or refractory acute myeloid leukemia. DFP-10917 is given as a 14-day continuous IV...

39 participants
Delta-Fly Pharma, Inc.
View Study Details

About Osteogenesis Imperfecta Clinical Trials in Charlottesville

Osteogenesis imperfecta is a group of genetic disorders mainly affecting the bones, causing them to break easily, often from little or no apparent cause. It is caused by defects in collagen production. Treatment includes bisphosphonates, physical therapy, and surgical rodding.

There are currently 5 osteogenesis imperfecta clinical trials recruiting participants in Charlottesville, VIRGINIA. These studies are seeking a combined 645 participants. Research is being sponsored by Chordia Therapeutics, Inc., Merck Sharp & Dohme LLC, Crinetics Pharmaceuticals Inc. and 2 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Osteogenesis Imperfecta Clinical Trials in Charlottesville — FAQ

Are there osteogenesis imperfecta clinical trials in Charlottesville?

Yes, there are 5 osteogenesis imperfecta clinical trials currently recruiting in Charlottesville, VIRGINIA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Charlottesville?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Charlottesville research site will contact you about next steps.

Are clinical trials in Charlottesville free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Charlottesville studies also compensate for your time and travel.

What osteogenesis imperfecta treatments are being tested?

The 5 active trials in Charlottesville are testing new therapies including novel drugs, biologics, and treatment approaches for osteogenesis imperfecta.

Data updated March 2, 2026 from ClinicalTrials.gov